Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook

TIPRANKS07-31

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on EPRX stock, giving a Buy rating on July 21. Lachlan Hanbury Brow...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655356027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 16:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655356027","market":"fut","top_or_hot":-1,"title":"Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook","media":"TIPRANKS","content":"<div>\n<p>William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on EPRX stock, giving a Buy rating on July 21. Lachlan Hanbury Brow...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-backed-by-ep-104gis-seamless-fit-into-gi-practice-and-strong-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-31 16:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-backed-by-ep-104gis-seamless-fit-into-gi-practice-and-strong-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on EPRX stock, giving a Buy rating on July 21. Lachlan Hanbury Brow...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-backed-by-ep-104gis-seamless-fit-into-gi-practice-and-strong-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EP","symbol_name":"Empire Petroleum Corp","start_time":0,"source_url":"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-backed-by-ep-104gis-seamless-fit-into-gi-practice-and-strong-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","article_id":"2655356027","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-backed-by-ep-104gis-seamless-fit-into-gi-practice-and-strong-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655356027","pubTimestamp":1785486936,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on EPRX stock, giving a Buy rating on July 21. Lachlan Hanbury Brow...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"EP":"Empire Petroleum Corp","EPRX":"Eupraxia Pharmaceuticals"},"translate_title":"Eupraxia Pharmaceuticals： EP-104GI 与胃肠道实践的无缝契合和强劲的商业前景支持买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPRX":1.5,"EP":1.5},"content_text":"William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on EPRX stock, giving a Buy rating on July 21. Lachlan Hanbury Brow...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655356027","isCrawlerRequest":true}